BACKGROUND: During the initial 26-week SPARK (Safety Paediatric efficAcy phaRmacokinetic with Kuvan®) study, addition of sapropterin dihydrochloride (Kuvan®; a synthetic formulation of the natural cofactor for phenylalanine hydroxylase, tetrahydrobiopterin; BH4), to a phenylalanine (Phe)-restricted diet, led to a significant improvement in Phe tolerance versus a Phe-restricted diet alone in patients aged 0-4 years with BH4-responsive phenylketonuria (PKU) or mild hyperphenylalaninaemia (HPA). Based on these results, the approved indication for sapropterin in Europe was expanded to include patients < 4 years of age. Herein, we present results of the SPARK extension study (NCT01376908), evaluating the long-term safety, dietary Phe tolerance, blood Phe concentrations and neurodevelopmental outcomes in patients < 4 years of age at randomisation, over an additional 36 months of treatment with sapropterin. RESULTS: All 51 patients who completed the 26-week SPARK study period entered the extension period. Patients who were previously treated with a Phe-restricted diet only ('sapropterin extension' group; n = 26), were initiated on sapropterin at 10 mg/kg/day, which could be increased up to 20 mg/kg/day. Patients previously treated with sapropterin plus Phe-restricted diet, remained on this regimen in the extension period ('sapropterin continuous' group; n = 25). Dietary Phe tolerance increased significantly at the end of the study versus baseline (week 0), by 38.7 mg/kg/day in the 'sapropterin continuous' group (95% CI 28.9, 48.6; p < 0.0001). In the 'sapropterin extension' group, a less pronounced effect was observed, with significant differences versus baseline (week 27) only observed between months 9 and 21; dietary Phe tolerance at the end of study increased by 5.5 mg/kg/day versus baseline (95% CI - 2.8, 13.8; p = 0.1929). Patients in both groups had normal neuromotor development and growth parameters. CONCLUSIONS: Long-term treatment with sapropterin plus a Phe-restricted diet in patients who initiated sapropterin at < 4 years of age with BH4-responsive PKU or mild HPA maintained improvements in dietary Phe tolerance over 3.5 years. These results continue to support the favourable risk/benefit profile for sapropterin in paediatric patients (< 4 years of age) with BH4-responsive PKU. Frequent monitoring of blood Phe levels and careful titration of dietary Phe intake to ensure adequate levels of protein intake is necessary to optimise the benefits of sapropterin treatment. Trial registration ClinicalTrials.gov, NCT01376908. Registered 17 June 2011, https://clinicaltrials.gov/ct2/show/NCT01376908 .

BioMarin Europe Ltd London UK

Children's Hospital Kreiskliniken Reutlingen Germany

Department of Children and Adolescents 3rd Faculty of Medicine Charles University Prague Czech Republic

Division for Neuropaediatrics and Metabolic Medicine Centre for Paediatric and Adolescent Medicine University Hospital Heidelberg Heidelberg Germany

Dr Von Hauner Children's Hospital Munich Germany

Great Ormond Street Hospital London UK

Hacettepe University School of Medicine Ankara Turkey

Muenster University Children's Hospital Muenster Germany

Universita La Sapienza Rome Italy

Universitair Ziekenhuis Antwerpen Antwerp Belgium

University Children's Hospital University Medical Center Hamburg Eppendorf Martinistrasse 52 20246 Hamburg Germany

University Hospital Padua Italy

See more in PubMed

Scriver CR, Kaufman S, et al. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Scriver CR, et al., editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001.

Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376(9750):1417–1427. doi: 10.1016/S0140-6736(10)60961-0. PubMed DOI

Camp KM, et al. Phenylketonuria scientific review conference: state of the science and future research needs. Mol Genet Metab. 2014;112(2):87–122. doi: 10.1016/j.ymgme.2014.02.013. PubMed DOI

de Baulny HO, et al. Management of phenylketonuria and hyperphenylalaninemia. J Nutr. 2007;137(6 Suppl 1):1561S–1563S. doi: 10.1093/jn/137.6.1561S. PubMed DOI

van Wegberg AMJ, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12(1):162. doi: 10.1186/s13023-017-0685-2. PubMed DOI PMC

Ozalp I, et al. Newborn PKU screening in Turkey: at present and organization for future. Turk J Pediatr. 2001;43(2):97–101. PubMed

Vockley J, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med Off J Am Coll Med Genet. 2014;16(2):188–200. PubMed

Sanford M, Keating GM. Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia. Drugs. 2009;69(4):461–476. doi: 10.2165/00003495-200969040-00006. PubMed DOI

Muntau AC, et al. Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial. Orphanet J Rare Dis. 2017;12(1):47. doi: 10.1186/s13023-017-0600-x. PubMed DOI PMC

Biomarin. Kuvan SmPC. 2008; Available from: https://www.ema.europa.eu/documents/product-information/kuvan-epar-product-information_en.pdf.

Longo N, et al. Long-term developmental progression in infants and young children taking sapropterin for phenylketonuria: a two-year analysis of safety and efficacy. Genet Med Off J Am Coll Med Genet. 2015;17(5):365–373. PubMed

Longo N, et al. Long-term safety and efficacy of sapropterin: the PKUDOS registry experience. Mol Genet Metab. 2015;114(4):557–563. doi: 10.1016/j.ymgme.2015.02.003. PubMed DOI

Rocha JC, MacDonald A, Trefz F. Is overweight an issue in phenylketonuria? Mol Genet Metab. 2013;110(Suppl):S18–24. doi: 10.1016/j.ymgme.2013.08.012. PubMed DOI

Rocha JC, et al. Weight management in phenylketonuria: what should be monitored. Ann Nutr Metab. 2016;68(1):60–65. doi: 10.1159/000442304. PubMed DOI

Burrage LC, et al. High prevalence of overweight and obesity in females with phenylketonuria. Mol Genet Metab. 2012;107(1–2):43–48. doi: 10.1016/j.ymgme.2012.07.006. PubMed DOI

Holm VA, Knox WE. Physical growth in phenylketonuria: I. A retrospective study. Pediatrics. 1979;63(5):694–699. PubMed

Weglage J, et al. Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia. Pediatr Res. 2001;49(4):532–536. doi: 10.1203/00006450-200104000-00015. PubMed DOI

Wyrwich KW, et al. Evaluation of neuropsychiatric function in phenylketonuria: psychometric properties of the ADHD rating scale-IV and adult ADHD self-report scale inattention subscale in phenylketonuria. Value Health. 2015;18(4):404–412. doi: 10.1016/j.jval.2015.01.008. PubMed DOI

Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997;53(3):983–997. doi: 10.2307/2533558. PubMed DOI

See more in PubMed

ClinicalTrials.gov
NCT01376908